Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan
<b>Background/Objectives</b>: Although chronic infection by <i>Pseudomonas aeruginosa</i> among patients with bronchiectasis is associated with poor prognosis, the impact of antibiotics with <i>P. aeruginosa</i> coverage in patients with bronchiectasis who experie...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/13/12/1182 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850049505450262528 |
|---|---|
| author | Akihiko Hagiwara Hisayuki Shuto Ryohei Kudoh Shota Omori Kazufumi Hiramatsu Jun-ichi Kadota Kiyohide Fushimi Kosaku Komiya |
| author_facet | Akihiko Hagiwara Hisayuki Shuto Ryohei Kudoh Shota Omori Kazufumi Hiramatsu Jun-ichi Kadota Kiyohide Fushimi Kosaku Komiya |
| author_sort | Akihiko Hagiwara |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Although chronic infection by <i>Pseudomonas aeruginosa</i> among patients with bronchiectasis is associated with poor prognosis, the impact of antibiotics with <i>P. aeruginosa</i> coverage in patients with bronchiectasis who experienced bacterial pneumonia or exacerbation of bronchiectasis has not been fully investigated. <b>Methods</b>: This study targeted patients with bronchiectasis who were admitted to hospitals because of bacterial pneumonia or exacerbation of bronchiectasis between April 2018 and March 2020 using a national inpatient database in Japan. The association of antipseudomonal antibiotic treatment with in-hospital mortality was assessed after propensity score matching to adjust the patients’ backgrounds. <b>Results</b>: In total, 4943 patients with bacterial pneumonia and 1914 patients with exacerbation of bronchiectasis were included in this study. The in-hospital mortality rate did not differ between patients who did and did not receive antipseudomonal agents among patients with bacterial pneumonia (9.0% [185/2045] vs. 7.4% [151/2045]; <i>p</i> = 0.053) and those with exacerbation of bronchiectasis (5.2% [42/803] vs. 4.1% [33/803] group; <i>p</i> = 0.287). <b>Conclusions</b>: The use of antibiotics covering <i>P. aeruginosa</i> does not apparently improve prognosis in patients with bacterial pneumonia or exacerbation of bronchiectasis. A prospective study focusing on the impact of antibiotics covering <i>P. aeruginosa</i> among patients with bronchiectasis in whom <i>P. aeruginosa</i> is isolated is required. |
| format | Article |
| id | doaj-art-78cbf61d929a486a95804e9c8202e359 |
| institution | DOAJ |
| issn | 2079-6382 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj-art-78cbf61d929a486a95804e9c8202e3592025-08-20T02:53:41ZengMDPI AGAntibiotics2079-63822024-12-011312118210.3390/antibiotics13121182Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in JapanAkihiko Hagiwara0Hisayuki Shuto1Ryohei Kudoh2Shota Omori3Kazufumi Hiramatsu4Jun-ichi Kadota5Kiyohide Fushimi6Kosaku Komiya7Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, JapanRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, JapanRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, JapanRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, JapanRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, JapanRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, JapanDepartment of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, JapanRespiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu 879-5593, Oita, Japan<b>Background/Objectives</b>: Although chronic infection by <i>Pseudomonas aeruginosa</i> among patients with bronchiectasis is associated with poor prognosis, the impact of antibiotics with <i>P. aeruginosa</i> coverage in patients with bronchiectasis who experienced bacterial pneumonia or exacerbation of bronchiectasis has not been fully investigated. <b>Methods</b>: This study targeted patients with bronchiectasis who were admitted to hospitals because of bacterial pneumonia or exacerbation of bronchiectasis between April 2018 and March 2020 using a national inpatient database in Japan. The association of antipseudomonal antibiotic treatment with in-hospital mortality was assessed after propensity score matching to adjust the patients’ backgrounds. <b>Results</b>: In total, 4943 patients with bacterial pneumonia and 1914 patients with exacerbation of bronchiectasis were included in this study. The in-hospital mortality rate did not differ between patients who did and did not receive antipseudomonal agents among patients with bacterial pneumonia (9.0% [185/2045] vs. 7.4% [151/2045]; <i>p</i> = 0.053) and those with exacerbation of bronchiectasis (5.2% [42/803] vs. 4.1% [33/803] group; <i>p</i> = 0.287). <b>Conclusions</b>: The use of antibiotics covering <i>P. aeruginosa</i> does not apparently improve prognosis in patients with bacterial pneumonia or exacerbation of bronchiectasis. A prospective study focusing on the impact of antibiotics covering <i>P. aeruginosa</i> among patients with bronchiectasis in whom <i>P. aeruginosa</i> is isolated is required.https://www.mdpi.com/2079-6382/13/12/1182bronchiectasis<i>Pseudomonas aeruginosa</i>antibioticpneumoniaexacerbation of bronchiectasis |
| spellingShingle | Akihiko Hagiwara Hisayuki Shuto Ryohei Kudoh Shota Omori Kazufumi Hiramatsu Jun-ichi Kadota Kiyohide Fushimi Kosaku Komiya Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan Antibiotics bronchiectasis <i>Pseudomonas aeruginosa</i> antibiotic pneumonia exacerbation of bronchiectasis |
| title | Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan |
| title_full | Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan |
| title_fullStr | Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan |
| title_full_unstemmed | Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan |
| title_short | Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan |
| title_sort | impact of antipseudomonal antibiotics in patients with bronchiectasis who experienced exacerbation or developed pneumonia a nationwide study in japan |
| topic | bronchiectasis <i>Pseudomonas aeruginosa</i> antibiotic pneumonia exacerbation of bronchiectasis |
| url | https://www.mdpi.com/2079-6382/13/12/1182 |
| work_keys_str_mv | AT akihikohagiwara impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan AT hisayukishuto impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan AT ryoheikudoh impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan AT shotaomori impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan AT kazufumihiramatsu impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan AT junichikadota impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan AT kiyohidefushimi impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan AT kosakukomiya impactofantipseudomonalantibioticsinpatientswithbronchiectasiswhoexperiencedexacerbationordevelopedpneumoniaanationwidestudyinjapan |